Targeting histone deacetylases： perspectives for epigenetic-based therapy in cardio-cerebrovascular disease

• Published in: Journal of geriatric cardiology : JGC 2015-03, Vol.12 (2), p.153-164
• Main Authors: Wang, Zi-Ying, Qin, Wen, Yi, Fan
• Format: Article
• Language: English
• Subjects: CCVD; HDAC; Review; 催化结构域; 心脑血管疾病; 治疗; 组蛋白乙酰转移酶; 组蛋白去乙酰化酶; 表观遗传
• ISSN: 1671-5411
• DOI: 10.11909/j.issn.1671-5411.2015.02.010

Although the pathogenesis of cardio-cerebrovascular disease （CCVD） is multifactorial, an increasing number of experimental and clinical studies have highlighted the importance of histone deacetylase （HDAC）-mediated epigenetic processes in the development of cardio-cerebrovascular injury. HDACs are a family of enzymes to balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. To date, 18 mammalian HDACs are identified and grouped into four classes based on similarity to yeast orthologs. The zinc-dependent HDAC family currently consists of 11 members divided into three classes （class I, II, and IV） on the basis of structure, sequence homology, and domain organization. In comparison, class III HDACs （also known as the sirtuins） are composed of a family of NAD＋-dependent protein-modifying enzymes related to the Sir2 gene. HDAC inhibitors are a group of compounds that block HDAC activities typically by binding to the zinc-containing catalytic domain of HDACs and have displayed an- ti-inflammatory and antifibrotic effects in the cardio-cerebrovascular system. In this review, we summarize the current knowledge about classifications, functions of HDACs and their roles and regulatory mechanisms in the cardio-cerebrovascular system. Pharmacological tar- geting of HDAC-mediated epigenetic processes may open new therapeutic avenues for the treatment of CCVD.